Cure JM Medical Advisory Board Chair Wins Prestigious Award

Cure JM Foundation MAB Chair Dr. Lisa Rider and Dr. Fred Miller receive 2019 Global Genes RARE Champion of Hope Award for Research Collaboration on behalf of IMACS (International Myositis Assessment and Clinical Studies Group)

On September 20, Lisa Rider, MD, and Frederick Miller, MD, PhD, on behalf of The International Myositis Assessment and Clinical Studies Group (IMACS), received the "RARE Champion of Hope – Collaboration in Research" award from Global Genes, a rare disease patient advocacy organization. The "RARE Champion of Hope" award recognizes innovation in research and advocacy in rare diseases. The awards were chosen by a panel of rare disease experts from a list of over 100 individuals and organizations worldwide that were nominated by their peers for their notable efforts in rare disease advocacy, collaboration in research, science, medical care and treatment.

Global Genes Award Ceremony

Dr Fred Miller, Cure JM Founder Shari Hume, Dr Lisa Rider, Mary McGowan

IMACS is a coalition of physicians and researchers with experience and interest in myositis. The group works to improve the lives of children and adults who suffer from myositis by discovering better therapies through understanding the causes of these diseases. IMACS is part of the National Institute of Environmental Health Sciences (NIEHS) at the National Institutes of Health.

Recently Dr. Rider shared some thoughts on how IMACS' work may impact the care of juvenile myositis patients: "IMACS is researching both children and adults with myositis, and we've developed work in parallel, including validated outcome measures, response criteria, classification criteria and clinical trials. There are many similar issues in both the children and adults, and the work will facilitate better care of our juvenile patients when they reach adulthood. This work has also integrated JM into the whole myositis spectrum and created better awareness of JM."

On receiving the award, Dr. Rider said, “It’s an honor to receive this award on behalf of IMACS. It’s all of IMACS that’s receiving this award. I think it’s powerful that all of these researchers are working together to better the lives of myositis patients and I think Global Genes recognition will better the recognition of JM around the world.”

Dr. Rider has devoted her career to JM research, helping to advance understanding of juvenile myositis. She has been a leader in fostering international collaborations that have helped further advance juvenile myositis research. She is the Deputy Chief of the Environmental Autoimmunity Group at the National Institute of Environmental Health Sciences, National Institutes of Health. She is also the Director of IMACS, the International Myositis Assessment and Clinical Studies Group. She’s been a member of Cure JM’s Medical Advisory Board since 2011 and was appointed as Chair in 2016.